Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2014

01.07.2014 | Preclinical study

Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers

verfasst von: Tarek Abdel-Fatah, Arvind Arora, Devika Agarwal, Paul Moseley, Christina Perry, Nicola Thompson, Andrew R. Green, Emad Rakha, Stephen Chan, Graham Ball, Ian O. Ellis, Srinivasan Madhusudan

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a serine threonine kinase belonging to the PIKK family (phosphoinositide 3-kinase-like-family of protein kinase), is a critical component of the non-homologous end-joining pathway required for the repair of DNA double-strand breaks. DNA-PKcs may be involved in breast cancer pathogenesis. We evaluated clinicopathological significance of DNA-PKcs protein expression in 1,161 tumours and DNA-PKcs mRNA expression in 1,950 tumours. We correlated DNA-PKcs to markers of aggressive phenotypes, DNA repair, apoptosis, cell cycle regulation and survival. Low DNA-PKcs protein expression was associated with higher tumour grade, higher mitotic index, tumour de-differentiation and tumour type (ps < 0.05). The absence of BRCA1, low XRCC1, low SMUG1, low APE1 and low Polβ was also more likely in low DNA-PKcs expressing tumours (ps < 0.05). Low DNA-PKcs protein expression was significantly associated with worse breast cancer-specific survival (BCSS) in univariate and multivariate analysis (ps < 0.01). At the mRNA level, similarly, low DNA-PKcs was associated with poor BCSS. In patients with ER-positive tumours who received endocrine therapy, low DNA-PKcs (protein and mRNA) was associated with poor survival. In ER-negative patients, low DNA-PKcs mRNA remains significantly associated with adverse outcome. Our study suggests that low DNA-PKcs expression may have prognostic and predictive significance in breast cancers.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Hill R, Lee PW (2010) The DNA-dependent protein kinase (DNA-PK): more than just a case of making ends meet? Cell Cycle 9(17):3460–3469PubMedCrossRef Hill R, Lee PW (2010) The DNA-dependent protein kinase (DNA-PK): more than just a case of making ends meet? Cell Cycle 9(17):3460–3469PubMedCrossRef
9.
10.
Zurück zum Zitat Hu Z, Liu H, Wang H, Miao R, Sun W, Jin G et al (2008) Tagging single nucleotide polymorphisms in phosphoinositide-3-kinase-related protein kinase genes involved in DNA damage “checkpoints” and lung cancer susceptibility. Clin Cancer Res 14(9):2887–2891. doi:10.1158/1078-0432.CCR-07-1822 PubMedCrossRef Hu Z, Liu H, Wang H, Miao R, Sun W, Jin G et al (2008) Tagging single nucleotide polymorphisms in phosphoinositide-3-kinase-related protein kinase genes involved in DNA damage “checkpoints” and lung cancer susceptibility. Clin Cancer Res 14(9):2887–2891. doi:10.​1158/​1078-0432.​CCR-07-1822 PubMedCrossRef
15.
16.
17.
Zurück zum Zitat Abdel-Fatah TM, Russell R, Agarwal D, Moseley P, Abayomi MA, Perry C et al (2014) DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol Oncol 8(3):520–532. doi:10.1016/j.molonc.2014.01.001 PubMedCrossRef Abdel-Fatah TM, Russell R, Agarwal D, Moseley P, Abayomi MA, Perry C et al (2014) DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol Oncol 8(3):520–532. doi:10.​1016/​j.​molonc.​2014.​01.​001 PubMedCrossRef
18.
Zurück zum Zitat Abdel-Fatah TM, Perry C, Moseley P, Johnson K, Arora A, Chan S et al (2014) Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer. Breast Cancer Res Treat 143(3):411–421. doi:10.1007/s10549-013-2820-7 PubMedCrossRef Abdel-Fatah TM, Perry C, Moseley P, Johnson K, Arora A, Chan S et al (2014) Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer. Breast Cancer Res Treat 143(3):411–421. doi:10.​1007/​s10549-013-2820-7 PubMedCrossRef
19.
Zurück zum Zitat Abdel-Fatah TM, Albarakati N, Bowell L, Agarwal D, Moseley P, Hawkes C et al (2013) Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. Breast Cancer Res Treat 142(3):515–527. doi:10.1007/s10549-013-2769-6 PubMedCrossRef Abdel-Fatah TM, Albarakati N, Bowell L, Agarwal D, Moseley P, Hawkes C et al (2013) Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. Breast Cancer Res Treat 142(3):515–527. doi:10.​1007/​s10549-013-2769-6 PubMedCrossRef
20.
Zurück zum Zitat Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/JCO.2013.50.9984 PubMedCrossRef Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.​1200/​JCO.​2013.​50.​9984 PubMedCrossRef
22.
Zurück zum Zitat Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352PubMedCentralPubMed Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352PubMedCentralPubMed
26.
Zurück zum Zitat Lee HS, Choe G, Park KU, Park do J, Yang HK, Lee BL et al (2007) Altered expression of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) during gastric carcinogenesis and its clinical implications on gastric cancer. Int J Oncol 31(4):859–866PubMed Lee HS, Choe G, Park KU, Park do J, Yang HK, Lee BL et al (2007) Altered expression of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) during gastric carcinogenesis and its clinical implications on gastric cancer. Int J Oncol 31(4):859–866PubMed
28.
29.
Zurück zum Zitat Shao SL, Cai Y, Wang QH, Yan LJ, Zhao XY, Wang LX (2007) Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance. Zhonghua zhong liu za zhi (Chin J Oncol) 29(9):697–700 Shao SL, Cai Y, Wang QH, Yan LJ, Zhao XY, Wang LX (2007) Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance. Zhonghua zhong liu za zhi (Chin J Oncol) 29(9):697–700
30.
Zurück zum Zitat Soderlund Leifler K, Queseth S, Fornander T, Askmalm MS (2010) Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol 37(6):1547–1554PubMed Soderlund Leifler K, Queseth S, Fornander T, Askmalm MS (2010) Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol 37(6):1547–1554PubMed
Metadaten
Titel
Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers
verfasst von
Tarek Abdel-Fatah
Arvind Arora
Devika Agarwal
Paul Moseley
Christina Perry
Nicola Thompson
Andrew R. Green
Emad Rakha
Stephen Chan
Graham Ball
Ian O. Ellis
Srinivasan Madhusudan
Publikationsdatum
01.07.2014
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3035-2

Weitere Artikel der Ausgabe 2/2014

Breast Cancer Research and Treatment 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.